
A value investing podcast. Antipodes is an active global equities investment manager, with offices in Sydney and London. Hear from the Antipodes team and other external thought leaders as they deliver investment updates and share perspectives on companies, macroeconomic trends and investment opportunities across the globe.
Episodes

Monday Dec 05, 2022
Investing in Emerging Markets
Monday Dec 05, 2022
Monday Dec 05, 2022
In this episode, Alison Savas, talks with Antipodes Emerging Markets co-portfolio managers Sunny Bangia and John Stavliotis.
They discuss why investors should consider Emerging Markets now, along with some of the key opportunities across emerging economies - including Mexico, Indonesia and Brazil.

Friday Nov 04, 2022
Friday Nov 04, 2022
Escalating geopolitical tensions, Xi Jinping’s consolidation of power in China, and the US Fed’s economic ‘balancing act’ are some the most significant issues dominating the macroeconomic backdrop for global investors as we move into the final quarter of the calendar year.
In Part 1 (00:30) of this new podcast episode, Alison Savas and Sunny Bangia provide listeners an insight into the way Antipodes is approaching these global affairs and the anticipated consequences for investors.
In Part 2 (20:00), Alison and Sunny provide an update on Antipodes’ portfolio positioning and discuss portfolio holdings, Merck and Co (NYSE: MRK) and Diageo (LON: DGE)*.
Antipodes website: antipodes.com
Antipodes on Linkedin: Antipodes Partners
*Individual stock commentary is illustrative only and not a recommendation to buy, hold, or sell any security.

Tuesday Oct 11, 2022
Antipodes’ approach to shorting
Tuesday Oct 11, 2022
Tuesday Oct 11, 2022
Through the recent decade-long bull market many have viewed short positions as simply a drag on performance. But in 2022 the regime has shifted. Portfolio protection has come back to the fore with the S&P 500 shedding around a quarter of its value so far this year, and concerns about global economic growth and central bank policy rising.
In this episode, Alison Savas and Jacob Mitchell discuss Antipodes’ approach to short selling and examine the case for Snap Inc. (NYSE: SNAP).

Saturday Aug 27, 2022
RWE’s Michael Muller on Europe’s power crunch
Saturday Aug 27, 2022
Saturday Aug 27, 2022
German energy giant, RWE, is faced with the challenge of helping to power a continent in the midst of a power crunch, while at the same time working towards ambitious decarbonisation targets.
In this episode, Alison Savas, talks to RWE's Chief Financial Officer, Michael Muller on the energy crisis, decarbonisation and RWE's operations.

Tuesday Aug 02, 2022
Quarterly update: The time for a contrarian mindset (Q2 2022)
Tuesday Aug 02, 2022
Tuesday Aug 02, 2022
In this quarterly market update episode Alison Savas and Antipodes CIO, Jacob Mitchell, discuss the state of equity markets in Q2 2022 and Antipodes bigger picture views on global investing and portfolio positioning.

Sunday Jun 26, 2022
Seagate Technology : Uncovering value amid the Nasdaq bear market
Sunday Jun 26, 2022
Sunday Jun 26, 2022
Disclaimer:
All content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269), the Antipodes Global Fund – Long (ARSN 118 075 764), the Antipodes Global Fund (ARSN 087 719 515), and the Antipodes Asia Fund (ARSN 096 451 393) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Funds and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.
The information provided is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Funds, you should consider the current product disclosure statement (PDS) and Target Market Determination (‘TMD’) of the Funds and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser.
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Funds. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this content. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.

Wednesday Jun 01, 2022
Meta & the battle for digital advertising supremacy
Wednesday Jun 01, 2022
Wednesday Jun 01, 2022
Alison Savas is joined by digital advertising expert Ben Legg to discuss the digital advertising landscape, in particular how Meta (NASDAQ: FB) is positioned following the recent fall in its stock price.
Key discussion points include:
- 4:00: Overview of how online advertise works today.
- 7:30: The digital advertising landscape and why digital advertising as a percentage of GDP is expected to grow.
- 10:50: The rise of Tik Tok
- 12:00: Meta's advertising technology and why it’s seen as being superior
- 21:10: How Facebook is moving to maintain user engagement
- 28.30: Can Instagram become the world’s biggest fashion retailer?

Monday May 02, 2022
Monday May 02, 2022
By the end of March, the S&P was only 5% shy of its all-time highs set in early January despite intensifying geopolitical and economic uncertainty. In fact, in early March US equities staged one of the largest and fastest bear market rallies since 1928. But the move back into the growthier tech complex in the US has now faded into April.
In this Q1 2022 market update, Alison Savas and Sunny Bangia discuss:
- 01:30: Why Stagflation has become Antipodes’ ‘base case’
- 04:40: The risk of Central Bank policy error
- 07:50: Antipodes’ portfolio positioning
- 10:30: Why Antipodes in holding the line on Chinese stocks
- 26:00: Antipodes’ China exposures

Wednesday Mar 30, 2022
Energy and commodities: strengthening portfolios today, but what about the future?
Wednesday Mar 30, 2022
Wednesday Mar 30, 2022
The war in Ukraine has seen the fragility of global energy and commodity markets laid bear. In this episode hear why Antipodes' investment team has been increasing exposure to energy and commodity stocks in recent years, the impact of sanctions on Russia and the longer-term outlook for the sectors.
In part two, hear a discussion about some of Antipodes' best investment ideas for exposure to longer-term energy and commodity trends.
Part 1 (1:00)
- Why Antipodes' global portfolios have been overweight energy.
- The impacts of the war in Ukraine on the energy and commodity sectors.
- Decarbonisation and the longer-term outlook for energy and commodities.
Part 2 (14:30)
- Technip Energies (EPA: TE) & Siemens Energy (ETR: ENR).
- Nutrien (TSE: NTR).
- Exposure to gold stocks - Newcrest Mining (ASX: NCM) & Barrick Gold (NYSE: GOLD).
For more investment insights visit antipodes.com

Monday Feb 28, 2022
Norsk Hydro: An aluminium giant for the new world
Monday Feb 28, 2022
Monday Feb 28, 2022
An interview with Pål Kildemo, Executive Vice President and Chief Financial Officer of Norsk Hydro (OSL: NHY).
Norsk Hydro has been a long-term holding in Antipodes' global portfolios. While it is one of the largest producers of aluminium globally, it is also has one of the lowest carbon footprints with its operations predominately powered using hydro electricity.
Disclaimer:
All content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269), the Antipodes Global Fund – Long (ARSN 118 075 764), the Antipodes Global Fund (ARSN 087 719 515), and the Antipodes Asia Fund (ARSN 096 451 393) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Funds and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.
The information provided is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Funds, you should consider the current product disclosure statement (PDS) and Target Market Determination (‘TMD’) of the Funds and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser.
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Funds. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this content. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance.